AR077328A1 - Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos - Google Patents

Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos

Info

Publication number
AR077328A1
AR077328A1 ARP100102667A ARP100102667A AR077328A1 AR 077328 A1 AR077328 A1 AR 077328A1 AR P100102667 A ARP100102667 A AR P100102667A AR P100102667 A ARP100102667 A AR P100102667A AR 077328 A1 AR077328 A1 AR 077328A1
Authority
AR
Argentina
Prior art keywords
alkyl
thioalkyl
alkoxy
halo
group
Prior art date
Application number
ARP100102667A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42629546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077328(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR077328A1 publication Critical patent/AR077328A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a su preparacion, a su uso médico, y a medicamentos que los comprenden. Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptable del mismo: en donde: X es O o S; R1 es hidrogeno; ciano; halogeno; alquilo C1-8; halo-alquilo C1-8; alcoxilo C1-8; halo-alcoxilo C1-8; tioalquilo C1-8; halo-tioalquilo C1-8; alcoxilo C1-8-alquilo C1-8; alcoxilo C1-8-alcoxilo C1-8; alcoxilo C1-8-tioalquilo C1-8; tioalquilo C1-8-alquilo C1-8; tioalquilo C1-8-alcoxilo C1-8; tioalquilo C1-8-tioalquilo C1-8; alquenilo C2-8; o alquinilo C2-8; R2 es un grupo arilo, heteroarilo, o heterociclilo no aromático G1, cuyo grupo G1 está opcionalmente sustituido por 1, 2, 3 o 4 sustituyentes seleccionados independientemente a partir del grupo que consiste en ciano, nitro, amino, amino-carbonilo, halogeno, alquilo C1-8; halo-alquilo C1-8; hidroxilo, alcoxilo C1-8; halo-alcoxilo C1-8; tioalquilo C1-8; halo-tioalquilo C1-8; alcoxilo C1-8-alquilo C1-8; alcoxilo C1-8-alcoxilo C1-8; alcoxilo C1-8-tioalquilo C1-8; tioalquilo C1-8-alquilo C1-8; tioalquilo C1-8-alcoxilo C1-8; tioalquilo C1-8-tioalquilo C1-8; alquenilo C2-8; alquinilo C2-8; alquenoxilo C2-8, alquinoxilo C2-8, y un grupo cicloalquilo C3-8, arilo, heteroarilo, o heterociclilo no aromático G2, cuyo grupo G2 está opcionalmente sustituido por 1, 2, 3 o 4 sustituyentes seleccionados independientemente a partir del grupo que consiste en ciano, aminocarbonilo, halogeno, alquilo C1-8; halo-alquilo C1-8; hidroxilo, alcoxilo C1-8; halo-alcoxilo C1-8; tioalquilo C1-8; halo-tioalquilo C1-8; alcoxilo C1-8-alquilo C1-8; alcoxilo C1-8-alcoxilo C1-8; alcoxilo C1-8-tioalquilo C1-8; tioalquilo C1-8-alquilo C1-8; tioalquilo C1-8-alcoxilo C1-8; tioalquilo C1-8-tioalquilo C1-8; alquenilo C2-8; y alquinilo C2-8; R3 es hidrogeno; ciano; halogeno; alquilo C1-8; halo-alquilo C1-8; alcoxilo C1-8; halo-alcoxilo C1-8; tioalquilo C1-8; halo-tioalquilo C1-8; alcoxilo C1-8-alquilo C1-8; alcoxilo C1-8-alcoxilo C1-8; alcoxilo C1-8-tioalquilo C1-8; tioalquilo C1-8-alquilo C1-8; tioalquilo C1-8-alcoxilo C1-8; tioalquilo C1-8-tioalquilo C1-8; alquenilo C2-8; o alquinilo C2-8; cualquiera de R4 es hidrogeno; ciano; halogeno; alquilo C1-8; halo-alquilo C1-8; alcoxilo C1-8; halo-alcoxilo C1-8; tioalquilo C1-8; halo-tioalquilo C1-8; alcoxilo C1-8-alquilo C1-8; alcoxilo C1-8-alcoxilo C1-8; alcoxilo C1-8-tioalquilo C1-8; tioalquilo C1-8-alquilo C1-8; tioalquilo C1-8-alcoxilo C1-8; tioalquilo C1-8-tioalquilo C1-8; alquenilo C2-8; o alquinilo C2-8; y R5 es hidrogeno; ciano; halogeno; alquilo C1-8; halo-alquilo C1-8; alcoxilo C1-8; halo-alcoxilo C1-8; tioalquilo C1-8; halo-tioalquilo C1-8; alcoxilo C1-8-alquilo C1-8; alcoxilo C1-8-alcoxilo C1-8; alcoxilo C1-8-tioalquilo C1-8; tioalquilo C1-8-alquilo C1-8; tioalquilo C1-8-alcoxilo C1-8; tioalquilo C1-8-tioalquilo C1-8; alquenilo C2-8; o alquinilo C2-8; o R4 y R5, tomados juntos, son -C(H)=C(H)-C(H)=C(H)- o un grupo alquileno C1-8, en cuyo grupo alquileno C1-8, 1 o 2 miembros -CH2- del anillo son opcionalmente reemplazados con miembros hetero del anillo independientemente seleccionados a partir del grupo que consiste en -N(H)-, -N[alquilo C1-8]-, -O-, -S-, -S(=O)- o -S(=O)2-; R6 es hidrogeno; alquilo C1-8; halo-alquilo C1-8; hidroxialquilo C1-8, alcoxilo C1-8-alquilo C1-8; mercapto-alquilo C1-8, tioalquilo C1-8-alquilo C1-8; amino-alquilo C1-8; N-alquilo C1-8-amino-alquilo C1-8; N,N-di-[alquilo C1-8]-aminoalquilo C1-8 con dos fracciones de alquilo C1-8 idénticas o diferentes en la fraccion de N,N-di-[alquilo C1-8]-amino; alquenilo C2-8; o alquinilo C2-8; E1 es -C(R7)-(R8)-; o -C(R7)-(R8)-C(Rg)-(R10)-; E2 es -C(R11)-(R12)-; o -C(R11)-(R12)-C(R13)-(R14)-; cualquiera de cada uno de R7 y R8 se selecciona independientemente a partir del grupo que consiste en hidrogeno, ciano, halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxilo C1-8-alquilo C1-8, y tioalquilo C1-8-alquilo C1-8; o R7 y R8, tomados juntos, son oxo o -CH2-CH2-; cualquiera de cada uno de R9 y R10 se selecciona independientemente a partir del grupo que consiste en hidrogeno, ciano, halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxilo C1-8-alquilo C1-8, y tioalquilo C1-8-alquilo C1-8; o R9 y R10, tomados juntos, son oxo o -CH2-CH2-; cualquiera de cada uno de R11 y R12 se selecciona independientemente a partir del grupo que consiste en hidrogeno, ciano, halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxilo C1-8-alquilo C1-8, y tioalquilo C1-8-alquilo C1-8; o R11 y R12, tomados juntos, son oxo o -CH2-CH2-; y cualquiera de cada uno de R13 y R14 se selecciona independientemente a partir del grupo que consiste en hidrogeno, ciano, halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxilo C1-8-alquilo C1-8, y tioalquilo C1-8-alquilo C1-8; o R13 y R14, tomados juntos, son oxo o -CH2-CH2-.
ARP100102667A 2009-07-24 2010-07-22 Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos AR077328A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22847209P 2009-07-24 2009-07-24
US25891109P 2009-11-06 2009-11-06
US36370210P 2010-07-13 2010-07-13

Publications (1)

Publication Number Publication Date
AR077328A1 true AR077328A1 (es) 2011-08-17

Family

ID=42629546

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102667A AR077328A1 (es) 2009-07-24 2010-07-22 Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos

Country Status (27)

Country Link
US (5) US8207164B2 (es)
EP (1) EP2456763B1 (es)
JP (1) JP5767214B2 (es)
KR (2) KR101422965B1 (es)
CN (1) CN102471293B (es)
AR (1) AR077328A1 (es)
AU (1) AU2010274913B2 (es)
CA (1) CA2768980A1 (es)
CL (1) CL2012000185A1 (es)
CO (1) CO6491058A2 (es)
CR (1) CR20120002A (es)
CU (1) CU24083B1 (es)
EA (1) EA201200174A1 (es)
EC (1) ECSP12011622A (es)
ES (1) ES2534315T3 (es)
GT (1) GT201200016A (es)
HK (1) HK1166314A1 (es)
IL (1) IL217378A (es)
MA (1) MA33450B1 (es)
MX (1) MX2012001070A (es)
NZ (1) NZ597529A (es)
PE (1) PE20121440A1 (es)
SG (1) SG177397A1 (es)
TW (1) TW201107316A (es)
UY (1) UY32799A (es)
WO (1) WO2011009943A1 (es)
ZA (1) ZA201200155B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
BRPI0617852A2 (pt) 2005-10-25 2011-08-09 Shionogi & Co compostos derivados de aminodi-hidrotiazina assim como composições contendo os mesmos
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
AR077328A1 (es) * 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
US8188079B2 (en) * 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
JP5600754B2 (ja) * 2009-12-31 2014-10-01 ノバルティス アーゲー ピラジン誘導体および神経障害の処置におけるそれらの使用
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US8673894B2 (en) * 2010-05-07 2014-03-18 Hoffmann-La Roche Inc. 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
EP2580200B1 (en) 2010-06-09 2016-09-14 Janssen Pharmaceutica, N.V. 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
JP5128019B1 (ja) * 2010-07-13 2013-01-23 ノバルティス アーゲー オキサジン誘導体および神経障害の処置におけるその使用
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
AU2011321427A1 (en) 2010-10-29 2013-05-02 Shionogi & Co., Ltd. Naphthyridine derivative
EP2655376B1 (en) 2010-12-22 2017-08-23 Janssen Pharmaceutica NV 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
US8524897B2 (en) * 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
JP2014505688A (ja) * 2011-01-12 2014-03-06 ノバルティス アーゲー オキサジン誘導体および神経障害の処置におけるその使用
PT2663561E (pt) 2011-01-13 2016-06-07 Novartis Ag Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos
MX2013008192A (es) * 2011-01-13 2013-12-16 Novartis Ag Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
US9242943B2 (en) * 2011-01-18 2016-01-26 Siena Biotech S.P.A. 1,4 oxazines as BACE1 and/or BACE2 inhibitors
US8399459B2 (en) 2011-02-02 2013-03-19 Hoffmann-La Roche Inc. 1,4 oxazines as BACE1 and/or BACE2 inhibitors
US8815841B2 (en) * 2011-02-18 2014-08-26 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
MX338333B (es) * 2011-03-01 2016-04-11 Janssen Pharmaceutica Nv DERIVADOS DE 6,7-DIHIDRO-PIRAZOLO [1,5ª]PIRAZIN-4-ILAMINA UTILES COMO INHIBIDORES DE BETA-SECRETASA (BACE).
US9067924B2 (en) * 2011-03-04 2015-06-30 Hoffmann-La Roche Inc. 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
CN103415521B (zh) 2011-03-09 2016-01-06 詹森药业有限公司 用作β分泌酶（BACE）抑制剂的3,4-二氢-吡咯并[1,2-a]吡嗪-1-基胺衍生物
US8748418B2 (en) * 2011-03-18 2014-06-10 Hoffmann-La Roche Inc. 1,4-oxazepines as BACE1 and/or BACE2 inhibitors
US8877744B2 (en) * 2011-04-04 2014-11-04 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
JP2014514302A (ja) 2011-04-13 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション Ｂａｃｅ阻害薬としての５−置換されたイミノチアジン類およびそれのモノおよびジオキシド、組成物およびそれらの使用
JPWO2012147763A1 (ja) 2011-04-26 2014-07-28 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
US9079919B2 (en) * 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
KR20140041590A (ko) * 2011-06-07 2014-04-04 에프. 호프만-라 로슈 아게 [1,3]옥사진
PE20140623A1 (es) * 2011-06-07 2014-05-30 Hoffmann La Roche Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
US8927535B2 (en) * 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
AU2012298983A1 (en) 2011-08-22 2014-02-27 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions and their use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
MX2014004479A (es) 2011-10-13 2014-08-01 Novartis Ag Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
UA111749C2 (uk) * 2011-12-05 2016-06-10 Янссен Фармацевтика Нв Похідні 6-дифторметил-5,6-дигідро-2h-[1,4]оксазин-3-аміну
ES2582473T3 (es) * 2011-12-06 2016-09-13 Janssen Pharmaceutica, N.V. Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2H-[1,4]oxazin-3-amina para el tratamiento de trastornos en que está implicada la beta-secretasa
AR089781A1 (es) * 2012-01-26 2014-09-17 Hoffmann La Roche Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
WO2014059185A1 (en) 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
AU2013363151A1 (en) 2012-12-20 2015-06-04 Merck Sharp & Dohme Corp. C5, C6 oxacyclic-fused iminothiazine dioxide compounds as BACE inhibitors
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US9751886B2 (en) 2013-06-12 2017-09-05 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)
WO2014198853A1 (en) 2013-06-12 2014-12-18 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
CN105452251B (zh) 2013-06-12 2017-12-26 詹森药业有限公司 作为β‑分泌酶(BACE)抑制剂的4‑氨基‑6‑苯基‑5,6‑二氢咪唑并[1,5‑A]吡嗪‑3(2H)‑酮衍生物
FR3025591B1 (fr) * 2014-09-05 2016-10-14 Technofan Dispositif de ventilation, aeronef comportant un tel dispositif de ventilation et procede de surveillance associe
KR20170095881A (ko) 2014-12-18 2017-08-23 얀센 파마슈티카 엔.브이. 베타―세크레타제의 ２,３,４,５―테트라히드로피리딘―６―아민 및 ３,４―디히드로―２ｈ―피롤―５―아민 화합물 억제제
TW201726651A (zh) * 2015-09-23 2017-08-01 健生藥品公司 ２，３，４，５－四氫吡啶－６－胺衍生物
CN109661397A (zh) * 2016-08-26 2019-04-19 伊莱利利公司 用作选择性bace1抑制剂的1,4-噁嗪类化合物
US10159191B2 (en) 2016-09-23 2018-12-25 Deere & Company Harvester grain unloader
CN110018266B (zh) * 2019-02-15 2022-03-04 广州市妇女儿童医疗中心 一种快速定量分析48种氨基酸的方法
CN112250580A (zh) * 2020-10-28 2021-01-22 上海昂卓新材料科技有限公司 一种2-硝基-2-取代苯基丙烷-1,3-二醇的制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (es) 1968-08-31 1970-03-03
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2005063738A1 (ja) 2003-12-29 2005-07-14 Banyu Pharmaceutical Co.,Ltd 新規２－へテロアリール置換ベンズイミダゾール誘導体
WO2005079802A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
TW200624426A (en) * 2004-09-21 2006-07-16 Lilly Co Eli BACE inhibitors
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
BRPI0617852A2 (pt) 2005-10-25 2011-08-09 Shionogi & Co compostos derivados de aminodi-hidrotiazina assim como composições contendo os mesmos
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
WO2008133273A1 (ja) * 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
US20100197688A1 (en) 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
TW201028381A (en) 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
US9237972B2 (en) 2008-12-16 2016-01-19 Kimberly-Clark Worldwide, Inc. Liquid surfactant compositions that adhere to surfaces and solidify and swell in the presence of water and articles using the same
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
AR077328A1 (es) 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
US20120238557A1 (en) 2009-11-13 2012-09-20 Shionogi & Co., Ltd. Aminothiazine or aminooxazine derivative having amino linker
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
US8673894B2 (en) * 2010-05-07 2014-03-18 Hoffmann-La Roche Inc. 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
US20130079349A1 (en) 2010-06-09 2013-03-28 Janssen Pharmaceutica Nv 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
EP2580200B1 (en) 2010-06-09 2016-09-14 Janssen Pharmaceutica, N.V. 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
JP5128019B1 (ja) * 2010-07-13 2013-01-23 ノバルティス アーゲー オキサジン誘導体および神経障害の処置におけるその使用
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
JP2014505688A (ja) 2011-01-12 2014-03-06 ノバルティス アーゲー オキサジン誘導体および神経障害の処置におけるその使用
MX2013008192A (es) 2011-01-13 2013-12-16 Novartis Ag Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
PT2663561E (pt) 2011-01-13 2016-06-07 Novartis Ag Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos
MX2014004479A (es) 2011-10-13 2014-08-01 Novartis Ag Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.

Also Published As

Publication number Publication date
EP2456763B1 (en) 2015-01-21
WO2011009943A1 (en) 2011-01-27
US20140113894A1 (en) 2014-04-24
ZA201200155B (en) 2012-09-26
EA201200174A1 (ru) 2012-08-30
CO6491058A2 (es) 2012-07-31
KR20140004810A (ko) 2014-01-13
AU2010274913A1 (en) 2012-02-02
KR101422965B1 (ko) 2014-07-23
CN102471293A (zh) 2012-05-23
CU20120013A7 (es) 2012-04-15
US20110021520A1 (en) 2011-01-27
CL2012000185A1 (es) 2012-10-12
CR20120002A (es) 2012-02-15
US20140088084A1 (en) 2014-03-27
CU24083B1 (es) 2015-03-30
SG177397A1 (en) 2012-02-28
TW201107316A (en) 2011-03-01
MX2012001070A (es) 2012-03-16
KR20120039655A (ko) 2012-04-25
EP2456763A1 (en) 2012-05-30
US20120238560A1 (en) 2012-09-20
GT201200016A (es) 2013-09-23
UY32799A (es) 2011-02-28
PE20121440A1 (es) 2012-11-06
ECSP12011622A (es) 2012-02-29
CN102471293B (zh) 2014-10-01
US20150018338A1 (en) 2015-01-15
JP2013500247A (ja) 2013-01-07
AU2010274913B2 (en) 2013-09-19
IL217378A (en) 2015-02-26
CA2768980A1 (en) 2011-01-27
HK1166314A1 (en) 2012-10-26
ES2534315T3 (es) 2015-04-21
US8207164B2 (en) 2012-06-26
MA33450B1 (fr) 2012-07-03
JP5767214B2 (ja) 2015-08-19
NZ597529A (en) 2013-11-29
IL217378A0 (en) 2012-03-01
US8846658B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR078408A1 (es) Derivados de indol como moduladores de los crac
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR089019A1 (es) Derivados modificados de 4-fenil-piridina
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR082885A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR077505A1 (es) Compuestos de piridina y sus usos
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
DOP2007000079A (es) Compuestos fenil amido heterocíclicos condensados
RU2015125591A (ru) БЕНЗИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ RORc
AR054890A1 (es) Derivados de quinolina como agentes antibacterianos
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR089568A1 (es) Compuestos heterociclicos y sus metodos de usos
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR054000A1 (es) Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo

Legal Events

Date Code Title Description
FB Suspension of granting procedure